Filing Analysis
Envoy Medical appointed Charles S. McKhann to its Board of Directors and Compensation Committee, increasing the board size from six to seven. Mr. McKhann is a veteran medical device executive with a history of leading companies through successful acquisitions by major players like Boston Scientific.
Key Facts
- Charles S. McKhann appointed as a Class I director on April 15, 2026, with a term expiring in 2027.
- Board size increased from six to seven members to accommodate the appointment.
- Mr. McKhann was granted 100,000 stock options at an exercise price of $0.72 per share, vesting over 36 months.
- Mr. McKhann's background includes serving as CEO of Silk Road Medical and Apollo Endosurgery, both of which were acquired by Boston Scientific Corporation.
Envoy Medical, Inc. dismissed Grant Thornton LLP and appointed EisnerAmper LLP as its new independent auditor effective March 25, 2026. The company's previous audit reports for 2024 and 2025 included going concern warnings and identified material weaknesses in internal controls.
Red Flags
- Persistent 'going concern' language in audit reports for the last two consecutive fiscal years.
- Ongoing material weaknesses in internal control over financial reporting (2024 and 2025).
- The filing was signed by an Interim Chief Financial Officer (Robert Potashnick), which may indicate management instability.
Key Facts
- Grant Thornton LLP was dismissed as the independent registered public accounting firm on March 25, 2026.
- EisnerAmper LLP was appointed for the fiscal year ending December 31, 2026, following a competitive process.
- Audit reports for fiscal years ended December 31, 2024, and December 31, 2025, contained explanatory paragraphs expressing substantial doubt about the Company’s ability to continue as a going concern.
- Material weaknesses in internal control over financial reporting were disclosed in the Company’s Annual Reports on Form 10-K for 2024 and 2025.
- No disagreements were reported between the Company and Grant Thornton on accounting principles, practices, or disclosures.
Envoy Medical, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, via a press release on March 23, 2026.
Red Flags
- Company continues to operate with an Interim CFO (Robert Potashnick).
Key Facts
- Announcement of Q4 and FY 2025 financial results.
- Press release dated March 23, 2026, furnished under Item 2.02.
- Filing signed by Interim CFO Robert Potashnick on March 27, 2026.
- The company is an emerging growth company.
Envoy Medical has regained compliance with Nasdaq's minimum market value of listed securities requirement (Rule 5550(b)(2)). While the company is no longer at immediate risk of delisting, it will be subject to a one-year discretionary panel monitor by Nasdaq.
Red Flags
- The company is subject to a one-year discretionary panel monitor, which acts as a 'probationary' period where any subsequent non-compliance could lead to accelerated delisting.
- History of listing standard deficiencies requiring a Hearing Panel intervention.
Key Facts
- Received Nasdaq confirmation of compliance on February 23, 2026.
- The compliance relates to Nasdaq Listing Rule 5550(b)(2) regarding market value.
- The company was previously under review by a Nasdaq Hearing Panel as of October 23, 2025.
- A discretionary panel monitor will be in effect for one year starting February 12, 2026, pursuant to Rule 5815(d)(4)(B).